Výsledky vyhledávání - "Masanao Sanagi"

Akademický článek

Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein

Autor: Aki Shimozawa, Yuuki Fujita, Hiromi Kondo, Yu Takimoto, Makoto Terada, Masanao Sanagi, Shin-ichi Hisanaga, Masato Hasegawa

Publikováno v: Frontiers in Neuroscience, Vol 13 (2019)

Parkinson’s disease (PD) and related disorders are characterized by filamentous or fibrous structures consisting of abnormal α-synuclein in the brains of patients, and the distributions and spread of these pathologies are closely correlated with d

Externí odkaz: https://doaj.org/article/398918e9ea8e4243ae5f726963d8920d

Zobrazit plný text záznamu

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptorγamong Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

Autor: Eiji Kurosaki, Masanao Sanagi, Hiroyuki Okumura, Hiroaki Masuzaki, Katsuhiko Gato, Kazuya Honbou, Akira Suwa, Takako Yonemoto, Tomohiko Yamaguchi, Yuko Kawasaki, Yuichi Tomura, Hirotoshi Kakuta, Tatsuya Niimi, Masaya Orita

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 349:10-20

A proportion of angiotensin II type 1 receptor blockers (ARBs) improves glucose dyshomeostasis and insulin resistance in a clinical setting. Of these ARBs, telmisartan has the unique property of being a partial agonist for peroxisome proliferator-act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321fb2363212fdae6a21d1505fcdfa4d
https://doi.org/10.1124/jpet.113.211722

Zobrazit plný text záznamu

Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels

Autor: Akira Fujimori, K Terai, H Nara, Kazuhiko Mizukami, Hiroyuki Itoh, Masamichi Okada, Masanao Sanagi, Koji Takakura, Shinji Fukushima

Publikováno v: British Journal of Pharmacology. 156:1267-1278

Background and purpose: Various complications consequent on disordered calcium and phosphate homeostasis occur frequently in chronic kidney disease (CKD) patients. Particularly, vascular calcification has high morbidity and mortality rates. There is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::187e00fddfacf717f2b290c04df84194
https://doi.org/10.1111/j.1476-5381.2008.00108.x

Zobrazit plný text záznamu

YM598, an Orally Active ETA Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-side Heart Failure in Rats with Cor Pulmonale and Myocardial Infarction

Autor: Takashi Miyauchi, Katsutoshi Goto, Satoshi Sakai, Masanao Sanagi, Katsumi Sudoh, Iwao Yamaguchi, Motoyuki Iemitsu, Akira Fujimori, Hironori Yuyama, Hisataka Shikama

Publikováno v: Journal of Cardiovascular Pharmacology. 44:S354-S357

The effects of the novel, selective endothelin-A (ET A ) receptor antagonist YM598 on both-side heart failure were investigated. Right-side heart failure secondary to pulmonary hypertension was produced by a single subcutaneous injection of 60 mg/kg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697396988cc5876d2352cbeaaebf9a83
https://doi.org/10.1097/01.fjc.0000166304.40937.0b

Zobrazit plný text záznamu

The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats

Autor: Masao Sasamata, Akiko Koakutsu, Keiji Miyata, Akira Fujimori, Katsumi Sudoh, Masanao Sanagi, Hironori Yuyama

Publikováno v: European Journal of Pharmacology. 496:129-139

We investigated the preventive and therapeutic effects of the selective endothelin ETA receptor antagonist potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylenthenesulfonamidate (YM598) on the development of pul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679916be6b27ddb3373c661f78d4dba1
https://doi.org/10.1016/j.ejphar.2004.06.021

Zobrazit plný text záznamu

Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction

Autor: Akira Fujimori, Kazumi Hayashi, Osamu Inagaki, Takeyuki Yatsu, Yuichi Tomura, Masayuki Tanahashi, Masanao Sanagi

Publikováno v: Pharmacological Research. 47:243-252

Several factors such as proteinuria and renal fibrosis may be important in the progression of many forms of chronic renal diseases. The purposes of the current study were to investigate the progressive renal failure of the rats with surgical renal ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d903629daa6e4cd5c873a1246f19cfb0
https://doi.org/10.1016/s1043-6618(02)00321-3

Zobrazit plný text záznamu

In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract

Autor: Masashi Ukai, Shuichi Sato, Masanao Sanagi, Akiyoshi Ohtake, Akiko Koakutsu, Keiji Miyata, Katsumi Sudoh, Masao Sasamata, Akira Fujimori, Hironori Yuyama

Publikováno v: European journal of pharmacology. 580(3)

We investigated the contractile response of the lower urinary tract to endothelin-1 in vitro (rabbits) and in vivo (dogs). We also assessed the effects of a selective endothelin ETA receptor antagonist, (E)-N-[6-methoxy-5-(2-methoxyphenoxy)[2, 2′-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f7571cd73f17df5c1139993502f45b
https://pubmed.ncbi.nlm.nih.gov/18078923

Zobrazit plný text záznamu

A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats

Autor: Masanao Sanagi, Keiji Miyata, Masao Sasamata, Yukiko Noguchi, Akira Fujimori, Katsumi Sudoh, Hironori Yuyama, Akiko Koakutsu

Publikováno v: Vascular pharmacology. 43(1)

The preventive effects of the novel and selective endothelin ET(A) receptor antagonist YM598 on the development of pulmonary hypertension (PH) were investigated in chronic hypoxia-induced PH rats. Oral administration of YM598 at a dose of 1 mg/kg was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa2fadd0f9c3f111d38af69b57fe856
https://pubmed.ncbi.nlm.nih.gov/15975532

Zobrazit plný text záznamu

Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist

Autor: Masanao Sanagi, Keiji Miyata, Hironori Yuyama, Katsumi Sudoh, Akiko Koakutsu, Akira Fujimori, Mikiko Yamanouchi Pharmaceutical Co. Ltd. Mori, Hironori Harada

Publikováno v: European journal of pharmacology. 478(1)

We describe here the pharmacology of (E)-N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenylethenesulfonamide monopotassium salt (YM598), a novel selective endothelin ET(A) receptor antagonist synthesized through the modification of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c20660185d1153c59b33aed8cd90544
https://pubmed.ncbi.nlm.nih.gov/14555186

Zobrazit plný text záznamu

Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists

Autor: Hideaki Nakahara, Susumu Watanuki, Masanao Sanagi, Masaya Orita, Akihiro Tanaka, Katsumi Sudoh, Shin-ichi Tsukamoto, Ryuji Tsuzuki, Jun-Ichi Kazami, Akira Fujimori, Hironori Harada, Isao Yanagisawa, Jun Shimaya

Publikováno v: Bioorganicmedicinal chemistry. 9(11)

In the previous paper, we described a series of 2-phenylethenesulfonamide derivatives, a novel class of ET(A)-selective endothelin (ET) receptor antagonists, including the 2-methoxyethoxy derivative 2a and the 2-fluoroethoxy derivative (2b). In this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fccc8c06fe302efd516309b6026de6d1
https://pubmed.ncbi.nlm.nih.gov/11597477

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání